Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo

Abstract

We covalently linked doxorubicin with a peptide that is hydrolyzable by prostate-specific antigen. In the presence of prostate tumor cells secreting prostate-specific antigen, the peptide moiety of this conjugate, L-377,202, was hydrolyzed, resulting in the release of leucine-doxorubicin and doxorubicin, which are both very cytotoxic to cancer cells. However, L-377,202 was much less cytotoxic than conventional doxorubicin to cells in culture that do not secrete prostate-specific antigen. L-377,202 was approximately 15 times more effective than was conventional doxorubicin at inhibiting the growth of human prostate cancer tumors in nude mice when both drugs were used at their maximally tolerated doses. Nude mice inoculated with human prostate tumor cells secreting prostate-specific antigen showed considerable reductions in tumor burden with minimal total body weight loss when treated with L-377,202. This improvement in therapeutic index correlated with the selective localization of leucine–doxorubicin and free doxorubicin in tissues secreting prostate-specific antigen after exposure to L-377,202.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Reduction in serum PSA levels.
Figure 2: Reduction in LNCaP tumor weights in nude mice treated with doxorubicin or L-377,202.
Figure 3: Changes in concentrations of leucine–doxorubicin and doxorubicin.

Similar content being viewed by others

References

  1. Husain, M.H., Blumenstein, B., Eisenberger, M. & Crawford, E.D. Southwest Oncology Group studies in hormone-refractory prostate cancer. Semin. Oncol. 23, 24–27 (1996).

    Google Scholar 

  2. Lilja, H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. 76, 1899–1903 (1985).

    Article  CAS  Google Scholar 

  3. Akiyama, K., Nakamura, T., Iwanaza, S. & Hara, M. The chymotrypsin-like activity of human prostate specific antigen, g-seminoprotein. FEBS LETTERS 235, 168–172 (1987)]

    Article  Google Scholar 

  4. Yu, H. et al. Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. J. Clin. Lab. Anal. 8, 251–253 (1994)

    Article  CAS  Google Scholar 

  5. Diamandis, E., Yu, H. & Sutherland, D.J.A. Detection of prostate specific antigen immunoreactivity in breast tumors. Breast Cancer Res. Tr. 32, 301–310 (1994).

    Article  CAS  Google Scholar 

  6. Yu, H., Diamandis, E. & Sutherland, D.J.A. Immunoreactive prostate specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin. Biochem. 27, 75–79 (1994).

    Article  CAS  Google Scholar 

  7. Levesque, M., Yu, H., D'Costa, M. & Diamandis, E. . Prostate specific antigen expression by various tumors. J. Clin. Lab. Anal. 9, 123–128 (1995).

    Article  CAS  Google Scholar 

  8. Diamandis, E. New diagnostic applications and physiological functions of prostate specific antigen. Scand. J. Clin. Lab. Invest. 55, 105–112 (1995).

    Article  Google Scholar 

  9. Catalona, W.J., Smith, D.S., Ratliff, T.L., Dodds, K. M., Coplen, d.e., Yuan, J. J., Petros, J.A., & Andriole, G.L., Measurement of Prostrate-specific antigen in serum as a screning test for Prostrae cancer. New England Journal of Medicine 324, 1156(1991).]

    Article  CAS  Google Scholar 

  10. Christensson, A., Laurell, C. & Lilja. H. . Enzymatic activity of prostate specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 194, 755–763 (1990).

    Article  CAS  Google Scholar 

  11. Leinonen, J., Zhang. W. & Stenman, U. . Complex formation between psa isoenzymes and protease inhibitors. J. Urol. 155, 1099–1103 (1996).

    Article  CAS  Google Scholar 

  12. Otto, A., Bar, J. & Birkenmeier, G. Prostate specific antigen forms complexes with human a2-macroglobulin and binds to the a2-macroglobulin receptor/ldl receptor-related protein. J. Urol. 159, 297–303 (1998).

    Article  CAS  Google Scholar 

  13. Christensson, A. & Lilja, H. Complex formation between protein C inhibitor and prostate specific antigen in vitro and in human semen. Eur. J. Biochem. 220, 45–53 (1994).

    Article  CAS  Google Scholar 

  14. Wainstein, M.A. et al. CWR22: androgen-dependent xenograft model derived from a primary prostatic carcinoma. Cancer Res. 54, 6049–6052 (1994).

    CAS  PubMed  Google Scholar 

  15. Denmeade, S.R. et al. Enzymatic activation of a doxorubicin-peptide prodrug by prostate specific antigen. Cancer Res. 58, 2537–2540 (1998).

    CAS  PubMed  Google Scholar 

  16. Tan, C. et al. Daunorubicin, an antitumoral antibiotic in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 20, 333–353 (1967).

    Article  CAS  Google Scholar 

  17. Macrez, C. et al. Accidents cardiaques observes en cours des traitment par rubidomycine. Pathol. Biol. 15, 949–953 (1967).

    CAS  PubMed  Google Scholar 

  18. Johansen, P.B. . Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother. Pharmacol. 5, 267–270 (1981).

    CAS  Google Scholar 

  19. Westfall, P.H. & Young, S.S. in Resampling Based Multiple Testing (John Wiley & Sons, New York, 1993). pp 112–145

    Google Scholar 

  20. SAS Institute. SAS/STAT Software: Changes and Enhancements Through Release 6.11. (SAS Institute, Cary, North Carolina, 1996).

  21. Dunnett, C.W. A multiple comparison procedure for comparing several treatments with a control. J. American Statistical Assoc. 50, 1096–1121 (1955).

    Article  Google Scholar 

  22. SAS Institute. SAS/STAT User's Guide Version 6, 4th edn. Vol. 2 (SAS Institute, Cary, North Carolina, 1990). pp 891–996

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Raymond E. Jones.

Rights and permissions

Reprints and permissions

About this article

Cite this article

DeFeo-Jones, D., Garsky, V., Wong, B. et al. A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med 6, 1248–1252 (2000). https://doi.org/10.1038/81351

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/81351

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing